Research output: Contribution to journal › Article › peer-review
Short-term renal and metabolic effects of low dose vildagliptin treatment added-on insulin therapy in non-proteinuric patients with type 2 diabetes : Open-label randomized prospective study. / Bayrasheva, Valentina K.; Pchelin, Ivan Y.; Dobronravov, Vladimir A.; Babenko, Alina Yu; Chefu, Svetlana G.; Shatalov, Ivan S.; Vasilkova, Volha N.; Hudiakova, Natalia V.; Ivanova, Alexandra N.; Andoskin, Pavel A.; Grineva, Elena N.
In: Archives of endocrinology and metabolism, Vol. 64, No. 4, 01.01.2020, p. 418-426.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Short-term renal and metabolic effects of low dose vildagliptin treatment added-on insulin therapy in non-proteinuric patients with type 2 diabetes
T2 - Open-label randomized prospective study
AU - Bayrasheva, Valentina K.
AU - Pchelin, Ivan Y.
AU - Dobronravov, Vladimir A.
AU - Babenko, Alina Yu
AU - Chefu, Svetlana G.
AU - Shatalov, Ivan S.
AU - Vasilkova, Volha N.
AU - Hudiakova, Natalia V.
AU - Ivanova, Alexandra N.
AU - Andoskin, Pavel A.
AU - Grineva, Elena N.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Objective: The aim of this randomized comparative study was to assess renal and metabolic effects of vildagliptin in insulin-treated type 2 diabetes (T2DM) patients without overt chronic kidney disease. Subjects and methods: We randomized 47 insulin-treated non-proteinuric patients with satisfactory controlled T2DM and estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2 either to continue insulin therapy (control) or to receive combined insulin-vildagliptin treatment (VIG group). We assessed eGFR using serum creatinine (eGFRcreat), cystatin C (eGFRcys), and both (eGFRcreat-cys), and urinary creatinine-adjusted excretion of albumin (UACR), type IV collagen (uCol IV/Cr), and neutrophil gelatinase-associated lipocalin (uNGAL/Cr) at baseline and after 6 months of treatment. Results: Study groups were comparable in terms of age and sex (60.1 ± 6.1 years and 42.9% men in control group vs. 60.8 ± 5.2 years and 39.1% in VIG group). After 6 months of treatment, there were no significant changes in main assessed parameters in control group. VIG group demonstrated significant decrease in HbA1c, diastolic blood pressure, frequency of hypoglycemia, and high-sensitivity C-reactive protein level as compared to the changes in control group. While eGFRcreat, UACR, and uNGAL/Cr showed no significant changes after vildagliptin addition, eGFRcys, eGFRcreat-cys, and uCol IV/Cr changed significantly in comparison with control group (+7.0% [3.7;13.3]; +5.1% [1.4;8.5];-32,8% [-55.8;-24.4], respectively, p < 0.01 each). Correlation and regression analysis revealed glucose-independent pattern of these changes. Conclusion: Addition of vildagliptin to ongoing insulin therapy in patients with T2DM was associated with a reduction in uCol IV/Cr and an increase in eGFRcys and eGFRcreat-cys, independent of T2DM control parameters.
AB - Objective: The aim of this randomized comparative study was to assess renal and metabolic effects of vildagliptin in insulin-treated type 2 diabetes (T2DM) patients without overt chronic kidney disease. Subjects and methods: We randomized 47 insulin-treated non-proteinuric patients with satisfactory controlled T2DM and estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2 either to continue insulin therapy (control) or to receive combined insulin-vildagliptin treatment (VIG group). We assessed eGFR using serum creatinine (eGFRcreat), cystatin C (eGFRcys), and both (eGFRcreat-cys), and urinary creatinine-adjusted excretion of albumin (UACR), type IV collagen (uCol IV/Cr), and neutrophil gelatinase-associated lipocalin (uNGAL/Cr) at baseline and after 6 months of treatment. Results: Study groups were comparable in terms of age and sex (60.1 ± 6.1 years and 42.9% men in control group vs. 60.8 ± 5.2 years and 39.1% in VIG group). After 6 months of treatment, there were no significant changes in main assessed parameters in control group. VIG group demonstrated significant decrease in HbA1c, diastolic blood pressure, frequency of hypoglycemia, and high-sensitivity C-reactive protein level as compared to the changes in control group. While eGFRcreat, UACR, and uNGAL/Cr showed no significant changes after vildagliptin addition, eGFRcys, eGFRcreat-cys, and uCol IV/Cr changed significantly in comparison with control group (+7.0% [3.7;13.3]; +5.1% [1.4;8.5];-32,8% [-55.8;-24.4], respectively, p < 0.01 each). Correlation and regression analysis revealed glucose-independent pattern of these changes. Conclusion: Addition of vildagliptin to ongoing insulin therapy in patients with T2DM was associated with a reduction in uCol IV/Cr and an increase in eGFRcys and eGFRcreat-cys, independent of T2DM control parameters.
KW - Cystatin C
KW - NGAL
KW - Renal function
KW - Type 2 diabetes
KW - Type IV collagen
KW - Vildagliptin
KW - cystatin C
KW - type IV collagen
KW - IV
KW - NEPHROPATHY
KW - BLOOD-PRESSURE
KW - VARIABILITY
KW - GLOMERULAR-FILTRATION-RATE
KW - type 2 diabetes
KW - CYSTATIN-C
KW - CREATININE
KW - HYPOGLYCEMIA
KW - renal function
KW - CHRONIC KIDNEY-DISEASE
KW - ASSOCIATION
UR - http://www.scopus.com/inward/record.url?scp=85089768284&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/8899fa9a-41ba-338d-a0af-cae837ffc379/
U2 - 10.20945/2359-3997000000220
DO - 10.20945/2359-3997000000220
M3 - Article
C2 - 32267348
AN - SCOPUS:85089768284
VL - 64
SP - 418
EP - 426
JO - Archives of endocrinology and metabolism
JF - Archives of endocrinology and metabolism
SN - 2359-3997
IS - 4
ER -
ID: 62429007